
# SSD Exposure Enhancement Report - Dr. Felipe Recommendations
Generated: 2025-06-15 22:28:12

## Enhancement Summary

### Drug Code Enhancements
- **Original ATC codes**: 4 classes (N05B, N05C, N02B, + basic)
- **Enhanced ATC codes**: 32 total codes
- **New drug classes added**:
  - Antidepressants (N06A): 7 codes
  - Anticonvulsants (N03A): 9 codes  
  - Antipsychotics (N05A): 13 codes

### Threshold Enhancement
- **Original threshold**: 90 days
- **Enhanced threshold**: 180 days (6 months)
- **Clinical rationale**: Dr. Felipe specified "six months or more" for persistent use

### Impact Analysis
- **H3 Original**: 2 patients
- **H3 Enhanced**: 3 patients
- **Net change**: +1 patients

### Drug Class Distribution
- **antidepressants_tricyclic**: 1 patients (avg 364 days)
- **anticonvulsants_other**: 1 patients (avg 364 days)
- **antipsychotics_atypical**: 1 patients (avg 364 days)


### Exposure Definition Impact
- **OR Logic Original**: 3 patients
- **OR Logic Enhanced**: 3 patients
- **Change**: +0 patients

### Validation Status
[COMPLETE] Missing drug classes added (N06A, N03A, N05A)
[COMPLETE] Duration threshold increased to 180 days
[COMPLETE] Backward compatibility maintained
[COMPLETE] Clinical rationale documented

### Next Steps
1. Update main analysis pipeline to use enhanced exposure
2. Validate clinical plausibility of enhanced patterns
3. Update research paper methodology section
4. Consider sensitivity analysis with original vs enhanced criteria
